Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), bought 1,764 shares at $14.23 ($25K) on 2021-12-29, disclosed to the SEC on 2022-01-03.
Open-market purchase of $25k BBIO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |